Novavax (NVAX)
(Delayed Data from NSDQ)
$20.97 USD
+3.21 (18.07%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $21.13 +0.16 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.97 USD
+3.21 (18.07%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $21.13 +0.16 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Zacks News
Novavax (NVAX) Inks COVID Jab Supply Deal With US Government
by Zacks Equity Research
Novavax (NVAX) inks a deal with the US government to supply 3.2 million doses of COVID shot. But the deal will be effective only if the vaccine gets EUA from the FDA. It also needs CDC recommendation.
Novavax (NVAX) Stock Rallies 26.8% in a Month: Here's Why
by Zacks Equity Research
FDA's advisory committee supports granting authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. The vaccine also receives authorization for use in adolescents in Europe.
Novavax (NVAX) COVID Jab Receives EU Nod for Adolescents
by Zacks Equity Research
Novavax (NVAX) obtains EU approval for its Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17.
Biotech Stock Roundup: VRTX's Regulatory Update, TYME Gains on Acquisition & More
by Zacks Equity Research
Regulatory and other updates from Vertex (VRTX) and TYME are a few key highlights from the biotech sector during the past week.
Novavax (NVAX) Stock Moves -0.81%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $51.43, marking a -0.81% move from the previous day.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $51.67, marking a -0.27% move from the previous day.
Novavax (NVAX) Up as EMA Recommends COVID Jab for Adolescents
by Zacks Equity Research
EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to Novavax's (NVAX) COVID-19 vaccine for use in adolescents. The stock rises 13.9%.
The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics
by Zacks Equity Research
Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.
FDA Committee Proposes EUA Nod to Novavax's (NVAX) COVID Jab
by Zacks Equity Research
An FDA advisory committee supports granting emergency use authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. Post the news, the stock rallies 20% in pre-market trading.
Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More
by Zacks Equity Research
Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Why Is Novavax (NVAX) Down 11.7% Since Last Earnings Report?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novavax (NVAX) Down After FDA Raises Concern for Its COVID Jab
by Zacks Equity Research
Before deciding the fate of Novavax's (NVAX) COVID-19 vaccine, a document issued by the FDA suggests that the vaccine may cause heart problems like myocarditis/pericarditis.
Novavax (NVAX) Down on Q1 Earnings and Sales Lagging Estimates
by Zacks Equity Research
Novavax (NVAX) misses on both earnings and sales for the first quarter of 2022. Its shares decline in after-hours trading following the result announcement.
Novavax (NVAX) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -23.12% and 19.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -41.18% and 23.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of -4.92% and 33.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) first-quarter earnings call, investor focus is likely to be on the sales figures of its COVID-19 vaccine.
BioNTech (BNTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) first-quarter earnings call, investors' focus is expected to be on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.
Novavax (NVAX) Surges 19.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) Q1 earnings call, investors are most likely to focus on the sales performance of its triple combo CF drug Trikafta/Kaftrio and updates on the non-CF pipeline.
Novavax (NVAX) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $45.07, moving +1.81% from the previous trading session.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.